China Officially Charges GSK Executives, Details Bribery Practices

China’s Ministry of Public Security has made formal bribery charges against UK-based drug maker GlaxoSmithKline and former general manager Mark Reilly and two Chinese executives for bribing non-government agencies and personnel.

BEIJING - After a 10-month investigation, China’s Ministry of Public Security (MPS) has formally charged that GlaxoSmithKline PLC ex-China head Mark Reilly and two Chinese executives offered bribes to boost pharmaceutical sales in China.

Reilly incorporated money used to pay bribes into the cost of drug sales since January 2009 when he became general...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By 

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By 

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.